Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Fineline Cube Sep 9, 2026
Company Drug

JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma

Fineline Cube Mar 9, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company Deals

Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac

Fineline Cube Mar 9, 2023

Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...

Company Deals

HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production

Fineline Cube Mar 9, 2023

China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand...

Company Deals

Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform

Fineline Cube Mar 9, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...

Company Deals

Sumitomo Pharma Secures Rights to Vibegron for Asian Markets

Fineline Cube Mar 8, 2023

Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...

Company Deals

Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies

Fineline Cube Mar 8, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Deals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

Fineline Cube Mar 8, 2023

China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...

Company Deals

F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS

Fineline Cube Mar 8, 2023

UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...

Company Drug

Biocytogen’s YH008 Gets NMPA Approval for Phase I Study

Fineline Cube Mar 8, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...

Company Deals

Heranova Closes $10M Seed Round for Women’s Health Solutions

Fineline Cube Mar 8, 2023

Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...

Company Drug

Inmagene’s Tavalisse First Prescribed in China for ITP Treatment

Fineline Cube Mar 8, 2023

China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...

Company Drug

AusperBio Initiates Phase I Trial for AHB-137 in New Zealand

Fineline Cube Mar 8, 2023

Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...

Policy / Regulatory

China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance

Fineline Cube Mar 8, 2023

The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...

Company Drug

BrightGene’s Generic Halaven Approved for Marketing in China

Fineline Cube Mar 7, 2023

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...

Company Deals

Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis

Fineline Cube Mar 7, 2023

UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...

Company Drug

Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine

Fineline Cube Mar 7, 2023

US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...

Policy / Regulatory

Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta

Fineline Cube Mar 7, 2023

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...

Company Deals

Neo Modulus Secures Series B Funding for Regenerative Medical Device Development

Fineline Cube Mar 7, 2023

Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...

Company Drug

Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions

Fineline Cube Mar 7, 2023

Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...

Policy / Regulatory R&D

Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies

Fineline Cube Mar 7, 2023

Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...

Posts pagination

1 … 606 607 608 … 718

Recent updates

  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.